Marketing plan 1

Contents of the marketing plan:

1. Executive summary P 3-4

2. Current market situation P 5-7

3. Opportunity and issue analysis P 8-9

4. Objectives P 10

5. Marketing strategy P 11-14

6. Action programs P 15

7. Financial projections P 16

8. Implementation controls P 17

Marketing plan 2
Company Profile:
Square Pharmaceuticals started their operation as a Partnership Firm. In 1964 they converted into
a Private Limited Company. In 1974 they conduct a technical Collaboration with Janssen
Pharmaceutical, Belgium, a subsidiary of Johnson & Johnson Intl, USA. In 1982 square
pharmaceuticals signed a licensing agreement with F. Hoffmann-La Roche Ltd., Switzerland. In
1985 they achieved market-leadership in the Pharmaceutical market of Bangladesh among all
national and multinational companies. In 1987 square become Pioneer in Pharmaceutical export
from Bangladesh. In 1991 they converted into public limited company. In 1994 they offered their
Initial Public Offering of Square Pharmaceutical shares. In 1995 Chemical Division of Square
Pharmaceuticals Ltd. starts production of pharmaceutical bulk products (API). In 1997 square
pharmaceuticals won the National Export trophy for exporting pharmaceuticals. In 1998 Agro-
chemicals & Veterinary Products division of Square Pharma starts its operation. In 2001 US
FDA/UK MCA standard new Pharmaceutical factory goes into operation built under the
supervision of Bovis Lend Lease, UK. In 2005 New State-of- the-Art Square Cephalosporin’s
Ltd. goes into operation; built under the supervision of TELSTAR S.A. of Spain as per US FDA/
UK MHRA requirements. In 2007 Square Pharmaceuticals Ltd., Dhaka Unit gets the UK MHRA
approval.

Marketing plan 3
SQUARE today symbolizes a name - a state of mind. But its journey to the growth and prosperity

has been no bed of roses. From the inception in 1958, it has today burgeoned into one of the top
line conglomerates in Bangladesh. Square Pharmaceuticals Ltd., the flagship company, is
holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985
and is now on its way to becoming a high performance global player.

VISION
Square view business as a means to the material and social wellbeing of the investors, employees
and the society at large, leading to accretion of wealth through financial and moral gains as a part
of the process of the human civilization.

MISSION
Square’s Mission is to produce and provide quality & innovative healthcare relief for people,
maintain stringently ethical standard in business operation also ensuring benefit to the
shareholders, stakeholders and the society at large.

OBJECTIVE
Square’s objectives are to conduct transparent business operation based on market mechanism
within the legal & social frame work with aims to attain the mission reflected by our vision.

Corporate focus
Square’s vision, mission and our Objectives are to emphasize on the Quality of product, process
and Services leading to growth of the Company imbibed with good Governance practices.

Marketing plan 4
Organizational Structure:

Board of Director

Chairman

Vice Chairman

Managing
Director

Director

Executive Executive
Resident Executive Executive
Director Director
Adviser Director Director
Admin Operation

Marketing plan 5
Training & Employee Development in Square

Square’s Training & Development enables their people to enhance their skills, keep them
updated with recent changes. They offer both on-the-job and off-the- job at both theoretical and
practical training opportunities through a range of Local, Regional and International Training
programs that include both functional and managerial levels on the basis of Training Need
Assessment. Training Need Analysis (TNA) is conducted by Department Heads and Human
Resource Department jointly on the basis of job analysis.

Management Development Training

Marketing plan 6
Round the year, management development training is organized for managers & executives at
Square’s Corporate Headquarters, Dhaka Unit & Pabna Unit. Our own and renowned resource
persons from home & abroad conduct the training sessions. They also send their employees to
renowned local training institutes for specialized training.

Overseas Training

Square sends their employee to abroad for training program depending on availability of
appropriate topics. Technical persons of their factories attend the Factory Assessment Test
(FAT) in various parts of the world for smooth operation of equipments.

Field Forces Training & Development

Each year, a significant number of Field Forces complete their induction training program and
joined to their respective markets and appear at examination in every month for further
development.

Field Forces Refresher Course

For updating product knowledge and selling skills of field forces, Refresher Course is organized
in four different regions in every month.

Territory Manager Training

Twice in every year, mid-level managers of sales participate in the training program titled “Sales
Territory Management” at a regular basis.

Marketing plan 7
Distribution:

Every year a number of Distribution Assistants (DA), Data Entry Operators (DEO) go under
induction training program immediately after initial recruitment. Each month, Refresher course
for DA, Driver and Packers is organized in two different depots for updating their knowledge.

Other Activities:

• Students of various universities are placed as Interns in different departments.

• Significant number of students completed their In-Plant Training in our Plants.
• Coordinating factory visit for different government and Institutions.
• All newly joined executives go through a structured Orientation Program.
• We conduct health, Hygiene & different awareness program for our colleagues.

Square conduct training on different compliance parameters for our factory colleagues.

1. Executive Summary

In Bangladesh cardiovascular diseases are increasing day by day. High cholesterol level in blood
is one of the important factors for developing cardiovascular complications.

For the treatment of high blood cholesterol, statins are the widely acceptable drugs. Presently 4
statins (Simvastatin, Atorvastatin, Fluvastatin, and Lovastatin) are available in Bangladesh.
Though there are a number of statins available worldwide, but considering the clinical profile,
Rosuvastatin is the best and it is known as the “Super Statin”. We always try to launch superior

Marketing plan 8
molecule first time. In this context, square proudly launches the Super Statin by the name
Rosuva®

If we consider the price, price of Rosuva tablet will be little bit high. Each tablet will cost Tk.
45.00. On the other hand the price of Lescol is Tk. 30 per tablet. But considering the clinical
efficacy, Rosuvastatin is superior to fluvastatin. In this case our objective is to target some
opinion moulders first for Rosuva tablet and special emphasis will be given to the doctors who
usually attend the patients belonging to high-class of the society.

Our expectation is Tk. 32, 60,352 in launching year from this product. Market size of Lipid
lowering agents is Tk.16, 39, 74,473. Our initial objective is to snatch 2% share from this
market segment. Pricing is crucial and we should have to overcome this limitation by aggressive
promotional activities. Product price is Tk. 45.00/- per tab. GM of the product is 50% with a
mark-up of 24%. Depending on successful workout on this product, we expect net profit of
596,565/- in the launching year.

Successful launching of this product will increase our pace in cardiovascular market. Definitely
we are going to do it.

Marketing plan 9
 Product Presentation:

Marketing plan 10
 2. Current Marketing Situation:

Square Pharmaceuticals has its independent department. It conducts the survey throughout the
country. With the help of MRPC Square can get the idea of prescription movement of Rosuva
as well as competitors brand. So Square can do their Mass marketing of Rosuva all over the
country.Respective Portfolio Executive will visit the customers to collect their feed back
regarding the product and study their satisfaction. So the current market situation of Rosuva is
increasing Day by Day. It’s doing very well in the market as a new comer. If we look at the
growth rate, sales trend, net income then we can easily understand the situation of Rosuva.
Rosuva is lised as growing product in the drug market.

Cholesterol & Triglyceride reducer Tk. 16,39,74,473

Growth 9.38%
Expected share from the market segment 2.5%
Expected value sale in first 12 months (Tk.) 3,260,352
Expected unit sale for first 12 months 9,600
Pack size 10's
Unit price (MRP+VAT) 450
Gross margin 50.00%
Mark-up 24%
Sample cost in first 12 months 180,000
Sample-sale ratio in first 12 months 6%
Promotional cost in first 12 months 455,000
Promotional cost-revenue in first 12 months 14%
Net profit before tax in first 12 months 596,565

Competitor’s analysis:

Direct Generic competitors

No direct competitor

Indirect Generic competitors

Brand Company Vaue sale/year (Tk.) Growth (%)

LESCOL Novartis 20,061,378 -8.51

Marketing plan 11
 TIGINOR Incepta 18,395,232 20.75

ATOVA Beximco 15,096,007 48.52

LIPICON Eskayef 11,137,054 -62.97

LIPITIN General 10,389,656 12.52

Sales trend of Top 10 manufacturers in Cholesterol & Triglyceride market:

35,000,000

30,000,000

25,000,000

2001
20,000,000
2002
2003
15,000,000
2004

10,000,000

5,000,000

0
INC EPTA PHA RM A SQUAR E BEX IM C O NOVA RTIS ESKAY EF GENERA L ORION LA B . OPSONIN C HEM R ENA TA DRU G
INTERNATIONA L

Growth (%) of10 manufacturers in Cholesterol & Triglyceride market:

2004 2003 2002 2001

Total market 9.38 33.08 99.59 127.60

Incepta pharma 32.70 69.41 462.96 999.00

Marketing plan 12
 Square 6.92 16.78 47.88 18.37

Beximco 31.99 29.39 -9.54 69.33

Novartis -8.51 -2.82 68.28 999.00

Eskayef -62.97 75.10 999.00 999.00

General 14.80 73.38 999.00 999.00

Orion lab. 197.64 999.00 0.00 0.00

Opsonin 45.42 4.90 999.00 999.00

Renata 41.69 -3.43 -11.94 72.25

Drug international 58.70 34.20 999.00 999.00

Marketing plan 13
Market share (%) of top 10 manufacturers in Cholesterol & Triglyceride
market:

MANUFACTURER 2004 2003 2002 2001 2000

INCEPTA PHARMA 13.40 11.05 8.68 3.08 0.00
SQUARE 12.41 12.69 14.46 19.52 37.53
BEXIMCO 12.28 10.18 10.47 23.10 31.05
NOVARTIS 12.23 14.63 20.03 23.76 0.00
ESKAYEF 6.79 20.06 15.25 1.63 0.00
GENERAL 6.46 6.16 4.73 0.52 0.00
ORION 5.97 2.19 0.00 0.00 0.00
OPSONIN 5.87 4.41 5.60 0.44 0.00
RENATA 5.77 4.45 6.14 13.91 18.38
DRUG INTERNATIONAL 5.76 3.97 3.94 0.31 0.00

Market share (%) of top 10 manufacturers in 2004:

5.76 13.4
5.77
5.87

5.97 12.41

6.46

6.79 12.28
12.23

INCEPTA PHARMA SQUARE BEXIMCO NOVARTIS

ESKAYEF GENERAL ORION OPSONIN
RENATA DRUG INTERNATIONAL

3. Opportunity and issue analysis

SWOT analysis of Rosuva: Generic Approach

Marketing plan 14
 SWOT Comparison Sheet
Generic Approach
Company Name Web Address EmployeesAnnual Revenue Net Asset Liabilities Busin Stock
Sales Income ess Value
Value

Square www.squarepharma.com.bd 3564 3162541 8257844 4411836 3500845 40

Pharmaceuticals (in (in (in (in
Ltd thousand) thousand) thousand) thousand)

Sun Pharma Ltd www.sunpharma.com 34605.6 3903.2 20559.4 19482.7 2314.7 No

(million) (million) (million) (million) (million) stocks in
market

SWOT Comparison Sheet (Strengths)

Sun Pharma (Rozavel)

Strengths Square (Rosuva)
• Long product range • Good image
What are your business
• Good quality image • Good quality
advantages?
• Strong field force
What are your core • State of the art manufacturing facility • Skilled in production
competencies? • Knowledgeable field force

Where are you making the most • Selling our product

• Finished pharmaceutical products
money?

• Antibiotics • Tablets and liquid syrup.

What are you doing well?
• Anti ulcerant products

Marketing plan 15
 SWOT Comparison Sheet (Weaknesses)
Sun Pharma (Rozavel)
Weaknesses Square (Rosuva)

What areas are you • Niche market

• N/A
avoiding?
Where do you lack • Human resouces Department
• Research and Development
resources?
What are you doing • Insulin products
• Chronic care products
poorly?
• Lyophilized injectable products • Liquid products
Where are you losing
money?
• Anti cancer products
What needs • Worker Effort
• Not applicable
improvement?

SWOT Comparison Sheet (Opportunity)

Sun Pharma (Rozavel)

Opportunities Square (Rosuva)
• Our workforce.
Any beneficial trends? • Technologies
Niches that competitors • Not applicable
• N/A
are missing?
• Generic Analysis
New technologies? • Insulin, Hormone
New needs of • Effective medicine
• Bio-tech products
customers?

SWOT Comparison Sheet (Threats)

Threats
Obstacles to overcome?
Aggressive competitors?
Square (Rosuva) Sun Pharma (Rozavel)
• Implementation WTO agreement • Production fault in 2005
after 2016
• Aristopharma, Renata • , Aristopharma, Popular

Successful competitors?
Negative economic
conditions?
Government regulation?
• Beximco, Square
• Popular, Incepta
pharmaceuticals ltd
• Current situation of Bangladesh
• Unrest political condition
• VAT on physician sample • VAT

Changing business • Unethical practice by the • Challenge by competitor

climate? competitors

Marketing plan 16
Vulnerabilities? • N/A • N/A

SWOT analysis of Rosuva: Functional Approach

Factor Rosuva (Square) Rozavel (Sun Pharma)

Strength Weakness Strength Weakness
Products 4 1 2 2
Price 5 0 1 4
Quality 4 1 3 2
Selection 4 1 3 2
Service 4 1 1 3
Reliability 4 1 2 4
Stability 4 1 1 4
Expertise 4 1 1 4
Company 5 0 1 4
Reputation
Location 5 0 1 4
Appearance 4 1 3 2
Sales 4 1 3 2
Method
Credit 2 3 4 2
Policies
Advertising 4 1 2 2
Image 5 1 1 4
Environmental (SW) Analysis- Comparison Sheet

Marketing plan 17
 Total= 62 - 14 29 - 45
48 16

Total SW of Square Total SW of Sun Pharma

(Rosuva) = 62 – 14 (Rozavel) =29 - 45
=48 = -16

Environmental (OT) Analysis- Comparison Sheet

Factor Rosuva (Square) Rozavel (Sun Pharma)

Opportunity Threat Opportunity Threat
Technology 4 1 2 3
Economy 4 1 2 2
Political 3 2 3 2
Legal 3 1 2 2
Service 4 1 2 1
Providers
International 4 1 3 2
Trade
People 4 1 3 2
Industry 3 3 2 2
Purchasing 3 1 2 3
Power
Social 3 1 2 3
Religious 4 1 1 3
Channel 1 0 0 0
Actors
Credit Policies 1 3 3 1
Media Access 1 1 1 1
Infrastructure 4 1 2 3
Total= 46 - 19 30 - 30

27 0

Marketing plan 18
 Total OT of Square Total OT of Sun pharma
( Rosuva) = 46 – 19 (Rozavel) =30 - 30
=27 =0

SWOT Analysis

Internal Factors External Factors

Strength Weakness Opportunities Threat

Strength:
1. Clinical superiority over other available statins
2. USFDA approved molecule
3. First time introduction in market
4. Good product presentation
5. Good corporate image of Square
6. Skilled filed force
7. Strong distribution network

Weakness:
1. High price
2. Due to high price limited number of consumer will be able to afford the drug.
3. Inadequate concentration on cardiovascular drugs

Opportunity & Threat:

Opportunity:

Marketing plan 19
 1. Prevalence of cardiovascular disease and hyperlipidemia is increasing day by day in
Bangladesh
2. Good market growth
3. Doctors are preferring statins as lipid lowering agent.
4. If raw materials price is fallen, it will help to reduce the price of the product and will
make the doctors comfortable to prescribe frequently which will increase market size.

Threat:
1. Launching of the molecule by other companies
2. Launching of the product with reduced price by other competitors
3. Unethical practices by some competitors (offering cash money, contract, etc.)

Marketing plan 20
4. Objectives:
• Financial objective:
a. Earn an annual rate of return on investment of 23.25%, which represents a
projected market share of 2.5%.
b. Produce net profit of Tk. 5.65 lac in one year
c. Achieve first-year total sales volume of Tk. 32.6 lac, based on an average price of
Tk. 450.00 per unit box.

• Marketing objective:
a. Achieve a first-year unit sales volume of 9,600 which represents a projected
market share of 2.5%
b. Generating brand awareness within the target customer through CME, Clinical
Meeting, Seminar, Symposia.
c. Generating a good footage in the cardiovascular market.

Marketing plan 21
5. Marketing strategy:

Target customers:
• Cardiologists
• Medicine specialists
• Competitors statin prescribers
Segmentation:
Market segmentation is one of the steps that goes into defining and targeting specific markets. It
is the process of dividing a market into a distinct group of buyers that require different products
or marketing mixes.

Opportunities in marketing increase when segmented groups of clients and customers with
varying needs and wants are recognized. Markets can be segmented or targeted using a variety of
factor. The bases for segmenting consumer markets include:

• Demographical bases (age, family size, life cycle, occupation)

• Geographical bases (states, regions, countries)
• Behavior bases (product knowledge, usage, attitudes, responses)
• Psychographic bases (lifestyle, values, personality)

But Rosuva is a lipid lowering drugs. Actually the marketing department of square doesn’t
segment only Rosuva market. It’s actually segmented its market for group of product or the same
kind of product. The marketer of Rosuva could ignore the differences in the segments, and
choose to aim a single product at all segments i.e. the whole market. This is typical in 'mass
marketing' or where differentiation is less important than cost.

Targeting
Targeting is the second stage of the SEGMENT "Target" process. After the market has been
separated into its segments, the marketer will select a segment or series of segments and 'target'
it.
Marketing plan 22
 Target customers:
• Cardiologists
• Medicine specialists
Competitors statin prescribers

Positioning:

Positioning strategy:

Square has positioned rosuva as the “super statin” and aggressive cholesterol
reducer to capture a separate place in the mind of the target market.

Marketing Mix Strategy:

Marketing mix strategy is the set of controllable, tactical marketing tools through
which the company influence the demand of their product and wants to get the response from the
target market. Square has five groups of variables which known as 5Ps in their marketing mix
strategy.

a.Product: is the goods and services that companies offers to the target
market.Square used forward invention for rosuva to meet the need for the treatment of
cardiovascular diseases.

b.Price: Price of each tablet of Rosuva is Tk. 45.00. This product belongs to the
high range of the lipid modifiers drug market. There are some statins available in the market in
lower price. But at present fluvastatin is available at Tk. 35 per tablet but clinically it not
superior to Rosuvastatin. This new generic is going to be introduced for the first time in
Bangladesh. This will provide a competitive edge over the available generics.

c.Place (Distribution channel): square has decided to distribute rosuva

Through their existing distribution channel and for this their objective is to supply the right
product in right place in right time.Initially this product will be made available to the nearby
chemist shops of the target doctors.

Marketing plan 23
 d.promotion
Square will use the following communication tools to promote Rosuva:
1. Literature
2. Physician sample
3. Booklet on Lipid modifying drugs
4. Gift- they also gives pen, mug, notepad etc
5. Continuous Medical Education (CME) program on Rosuvastatin
Promotional pattern:
b.
Av. Per Nationa
Criteria MPO l

No of target doctors in total 1 282

No of prescription served per month per doctor 2 564

1
No. of tablet served per prescription 5 8,460
Total no. of tablets served per month per 3
market 0 8,460
So, The Monthly Average Unit Sales Target will
be in box (1 X 10's) 3 846
3
So, the Yearly Sales Target will be : 6 10,152

• Promotional intensity:

Categor Number Promotional month

y
Detailing 04 July, August, October, April
Reminder 01 January
Gift 01 November
Detailing: Promotion with printed promotional material & physician’s sample
Reminder: Promotion with only physician’s sample

e.People: also refers to customer. Square specially targets the doctors as their
customaers who usually attend the patients from the high-class in the socity.

Marketing plan 24
 Rosuva is the “super statin” and aggressive cholesterol reducer

Control Measures:
Sales Force Control:
Square feels that the sales forecast figures are conservative. It will steadily increase sales as the
advertising budgets allows. Although the target market forecast listed all of the potential customers
divided into separate groups, the sales forecast group’s customers into two categories: Recreational and
competitive, reducing the number of categories allows the reader to quickly discern information, making
the char more functional.

Monthly Sales Forecast:

Sales Forecast
Sales 2008 2007 2006
Recreational $455,740 $598,877 $687,765
Competitive $72,918 $95,820 $110,042
Total Sales $528,658 $694,697 $797,807

Direct Cost of Sales 2008 2007 2006

Recreational $82,033 $107,798 $123,798
Competitive $13,125 $17,248 $19,808
Subtotal Cost of Sales $98,159 $125,046 $143,605

DISTRIBUTION CONTROL:
Rosuva has good distribution control all over the country. Initially this product will be made
available to the nearby chemist shops of the target doctors, for that they divide
The distribution channel in four zones’. Those are:-
• Dhaka.
• South.
• West.
• North.

Rosuva has its distribution channel among the following cities:-

1. Pabna

Marketing plan 25
 2. Dhaka
3. Chittagong
4. Comilla
5. Rajshahi
6. Barishl
7. Khulna
8. Sylhet
9. Rangpur
10. Bogra
11. Mymensingh
12. Faridpur
13. Tangail
14. Maizdee

Pricing Control:
Rosuva has a good price control among the market. Though price of each tablet of Rosuva is
quiet high. The price of each tablet is Tk. 45.00. There are some statins available in the market at
lower price; Such as Lesocol. The price of Lescol is Tk.30 per tablet, but considering the clinical
efficiency, Rosuvastain is superior to fluvastain. Actually our objective is to target some opinion
moulders first for Rosuva tablet and special emphasis will be given to the doctors who usually
attend the patients belonging to high-class of the society. High price is the main problem for
Rosuva, but it is going to be introduced new generic for the first time in Bangladesh. This will
provide a competitive edge over the available generics, by doing this we can overcome the
disadvantage of high price.

Marketing Research:
Square Pharmaceuticals has its own Market Research & Planning Cell (MRPC). It is an
independent department. It conducts the survey throughout the country. With the help of MRPC
we can get the idea of prescription movement of Rosuva as well as competitors brand.
Respective Portfolio Executive will visit the customers to collect their feed back regarding the

Marketing plan 26
product and study their satisfaction. The above tools will help to identify the opportunity and
make strategies according for the establishment of the product.

Marketing plan 27
Costing of Rosuva®

Cost/Pack
Particulars
(Tk)
R/M cost 155.77
P/M cost 3.99
(R/M + P/M) cost 159.76
Add: Wastage (5%) 1.2
Total Material (TM) cost 160.96
Conversion Cost :a certain % of TM cost & is
7.99
given in A&F proposed price, equal for both
Production cost (PC) 168.95
Add: Fixed Admin. Cost and Sell & Dist. Incl.
Discount (18% of TP) 61.13
Add : Marketing cost (8% of TP) 27.17
Total cost 257.25
Mark-up 82.37
TP 339.62
Add : VAT (16.5% of TP) 56.04
Add : Retailer's Comm. (16% of TP) 54.34
MRP + VAT 450.0
GM % 50
Mark Up % 24

Marketing plan 28
6. Budget allocation for Rosuva:

PROMOTIONAL PLAN SALES

GIFT AND FORECAST
Monthwise
breakdown PPM SAMPLE GIMMICKS (Rosuva 10)
Value Sale
PPM U.cost Qty. Total cost Sample U.cost Quantity Total cost U.cost Qty. T. cost
Units (Tk.)
July '07 Lit 8 5,000 40,000 2's 45.00 1,000 45,000 800 271,696
August '07 Pad 20 3,500 70,000 2's 45.00 1,000 45,000 800 271,696
September '07 800 271,696
October '07 SC 3 5,000 15,000 - 800 271,696
November '07 500 300 150,000 800 271,696
December '07 800 271,696
January '08 2's 45.00 1,000 45,000 800 271,696
February '08 800 271,696
March '08 800 271,696
April '08 Lit 8 5,000 40,000 2's 45.00 1,000 45,000 800 271,696
May '08 800 271,696
June '08 800 271,696
9,60
Total 18,500 125,000 4,000 180,000 300 150,000 0 3,260,352
Lit: Literature
SC: Showcard

Marketing plan 29
7. Financial projections

3,260,3
Revenue (Tk.) 52
97,
Less: 3% discount 811
3,162,
Net revenue (Tk.) 541
1,621,9
Less: COG 20
1,540,6
Gross margin (Tk.) 21

Less: Marketing expenses

180,
Physician's sample 000
275,
PPM + Gift 000
489,
Distribution expense 057
944,
Total expense 057
596
Net profit before tax (Tk.) ,565
Total expense as (%) of net
revenue 29.85%

Gross margin (%) in first year 47.25%

Total Investment 2,565,977

Return on investment 23.25%

Marketing plan 30
8. Implementation controls:

• Day to day sales monitoring with the help of Square Information Backup System

• As the price of the product is high. Continuous communication with suppliers regarding
the price of RM so that right decision can be taken in appropriate time to face the price
war

• Necessary steps are taken by commercial department for smooth procurement of the raw
materials

• Regular communication with the filed force for updated feedback regarding the
prescription movement of the product

• Analysis of market share data provided by Market Research & Planning Cell, to take
necessary measure for increasing/sustain market share

Marketing plan 31